ZOGENIX, INC.
ZGNX evidence brief
What we can confirm
- BioSniper Score:
- 7.9 / 10
- Lead Asset:
- fintepla (Phase 4)
What it means
What to watch
Prepared research question
What matters most for ZGNX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
fintepla (Phase 4)
Next Catalyst
—
Tracking 4 pipeline candidates · 11 clinical trials for ZOGENIX, INC..
Run ZOGENIX, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ZOGENIX, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Governance
Frequently asked questions
What is ZOGENIX, INC.'s lead drug candidate?
ZOGENIX, INC.'s most advanced tracked candidate is fintepla (Phase 4) for CDKL5 Deficiency Disorder (CDD).
Who is the CEO of ZOGENIX, INC.?
Stephen J. Farr, Ph.D. is the chief executive officer of ZOGENIX, INC. (ZGNX).
What therapeutic areas does ZOGENIX, INC. focus on?
ZOGENIX, INC. develops therapies across Neurology, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.